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Abstract
OBJECTIVE: Recent studies have suggested that cannabis use is a risk factor for developing
schizophrenia. We tested the hypothesis that cannabis use increases the likelihood of psychosis-like
experiences in non-clinical participants who scored highly on a measure of schizotypy. METHOD: The
psychological effects of cannabis were assessed in 137 healthy individuals (76% female, mean age 22
years) using a newly developed questionnaire concerned with subjective experiences of the drug: the
Cannabis Experiences Questionnaire. The questionnaire has three subscales: Pleasurable Experiences,
Psychosis-Like Experiences and After-Effects. Respondents also completed the brief Schizotypal
Personality Questionnaire. RESULTS: Cannabis use was reported by 72% of the sample. Use per se was
not significantly related to schizotypy. However, high scoring schizotypes were more likely to report both
psychosis-like experiences and unpleasant after-effects associated with cannabis use. The pleasurable
effects of cannabis use were not related to schizotypy score. CONCLUSION: High scoring schizotypes
who use cannabis are more likely to experience psychosis-like phenomena at the time of use, and
unpleasant after-effects. Our results are consistent with the hypothesis that cannabis use is a risk factor
for full psychosis in this group.
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Abstract
Objective: Recent studies have suggested that cannabis
use is a risk factor for developing schizophrenia. We tested the hypothesis that cannabis use increases the likelihood of psychosis-like experiences in non-clinical participants who scored highly on a measure of schizotypy.
Method: The psychological effects of cannabis were assessed in 137 healthy individuals (76% female, mean age
22 years) using a newly developed questionnaire concerned with subjective experiences of the drug: the Cannabis Experiences Questionnaire. The questionnaire has
three subscales: Pleasurable Experiences, PsychosisLike Experiences and After-Effects. Respondents also
completed the brief Schizotypal Personality Questionnaire. Results: Cannabis use was reported by 72% of the
sample. Use per se was not significantly related to schizotypy. However, high scoring schizotypes were more
likely to report both psychosis-like experiences and
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unpleasant after-effects associated with cannabis use.
The pleasurable effects of cannabis use were not related
to schizotypy score. Conclusion: High scoring schizotypes who use cannabis are more likely to experience
psychosis-like phenomena at the time of use, and unpleasant after-effects. Our results are consistent with the
hypothesis that cannabis use is a risk factor for full psychosis in this group.
Copyright © 2006 S. Karger AG, Basel

Introduction

It is accepted that the use of street drugs, including
cannabis, increases both the risk of relapse and severity
of symptoms in individuals already diagnosed with
schizophrenia [e.g. 1, 2]. According to van Os et al. [3],
cannabis use signiﬁcantly increases the risk of developing
a psychotic disorder in individuals with no previous history of illness and, additionally, predicts poor prognosis
in those with an established vulnerability.
An unresolved issue is whether people who are prone
to psychosis are drawn to cannabis use (an association
model), or whether cannabis use truly increases the incidence of psychotic experiences (a causal model) [e.g. 3–5].
Data from the recently reported cohort study by Arse-
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nault et al. [6] favour the causal model since cannabis use
in adolescence appears to be a risk factor for later psychosis. However results do not consistently indicate whether
a pre-existing biological vulnerability is necessary to
underpin the development of psychosis in the causal
model.
Researchers have frequently used self-report measures
of schizotypy in non-clinical samples as an index of psychosis proneness, and some studies have reported that
cannabis users have higher schizotypy scores than nonusers [7–10]. Skosnik et al. [11] have, for example, reported that current cannabis users had higher schizotypy
scores than either past users or those who had never used
cannabis. Cannabis use has long been associated with an
increase in the reporting of ‘psychosis-like’ experiences
[12–14]. Verdoux et al. [15] recently explored this association in relation to psychosis proneness determined
by structured interview. Using an experience sampling
method, researchers showed that both degree of psychosis
vulnerability and cannabis use were independently associated with unusual perceptual experiences.
We have developed a new questionnaire (the Cannabis
Experiences Questionnaire, CEQ) to enable cannabis users to record the various psychological effects they experience both as they smoke, and for some time after use. We
hypothesized that: (1) cannabis use would be associated
with higher schizotypy scores, and (2) that cannabis users
with high schizotypy scores would report more psychosislike experiences and after-effects under the inﬂuence of
the drug.

Method
Participants
Participants were recruited on an opportunity sample basis. Our
sample comprised 137 university students [33 (24.1%) males and
104 (75.9%) females; average age 22.01 (SD 5.50) years]. The participants were either completing single honours or combined studies courses which involved psychology or sociology (accounting for
the greater numbers of females to males in this sample). Participants received no ﬁnancial compensation for taking part in the
study.
Measures
Schizotypy
Participants completed the brief Schizotypal Personality Questionnaire (SPQB) [16], a 22-item questionnaire consisting of the
most reliable items taken from the longer Schizotypal Personality
Questionnaire [17]. The SPQB provides a total score and scores on
three sub-scales: ‘disorganized’ (SPQB-D), ‘cognitive-perceptual’
(SPQB-CP) and ‘interpersonal’ (SPQB-I).
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Drug Use
Participants were asked how often (everyday, more than once a
week, about once a week, about once a month, a few times each
year, about once a year, only once or twice, never) and when they
smoked cannabis (during the morning, during the day, during the
evening, frequently during the day and night). Information about
other drugs used for recreational purposes was also sought.
Experiences with Cannabis
The CEQ was developed speciﬁcally for this study to investigate
the subjective effects of cannabis. It consists of three subscales that
record respectively: pleasurable experiences, psychosis-like experiences and after-effects. The Pleasurable Experiences subscale consists of items such as: feeling happy, feeling laid back, able to understand the world better and so on [18]. Scores on this subscale
could range from 18 to 90. The Psychosis-Like Experiences subscale comprises psychological features akin to symptoms associated
with psychotic disorders: delusional thinking, experiencing auditory hallucinations, feeling paranoid etc. [e.g. 19, 20]. For this subscale scores could range from 25 to 125. The After-Effects subscale
attempts to quantify the consequences of cannabis (after) use and
consists of items associated with the ‘amotivational syndrome’
commonly reported in habitual users, e.g. loss of drive, reduced attention, feeling generally slowed down and so on [e.g. 21]. Scores
on this scale could range from 12 to 60. Participants completed the
CEQ by indicating on a ﬁve-point Likert scale (Never, Occasionally, Sometimes, More often than not, Always) the frequency of
each ‘experience’ (when using cannabis).
Procedure
Respondents were asked to complete both the CEQ and the
SPQB as fully and honestly as possible. The questionnaires were
completed by participants in their own time (either at home or in
the university) and returned to a labeled post box placed in a communal area of the university. An anonymisation procedure ensured
that respondents were identiﬁable by a number only. Data analysis
was performed using SPSS version 11.5. Non-normally distributed
data were transformed as appropriate. The study had full ethical
approval as part of a larger project examining psychosis risk factors
in a psychologically healthy population.

Results

72.5% of our sample reported having used cannabis at
least once. For these, the frequency of use broke down as
follows: everyday 6%, at least once a week 21%, at least
once a month 23%, at least once a year 26%, less than
once a year 23%. There were no gender differences in the
rates of cannabis use.
Fifty-two per cent of cannabis users had used only cannabis. Participants who used cannabis more frequently
(frequency use: at least once a week, a few times each
month and about once a year) reported using more recreational drugs [f(2, 95) = 4.11, p ! 0.02]. For those who
used cannabis once a week (n = 27) the mean number of
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drugs used was 2.15 (SD = 2.14); for those who used cannabis a few times each month (n = 48): 1.23 (1.82); for
those who had smoked cannabis about once a year (n =
23): 0.70 (1.43). The number of additional drugs used
varied between 1 (41% of the sample) and 10 (0.7% of the
sample) for the whole sample. Other recreational drugs of
choice (listed according to frequency of reporting) included cocaine (19%), ecstasy (19%), LSD (13%), amphetamine (11%), magic mushrooms (7%), poppers (7%) and
ketamine (4%). Drugs which were used by fewer than 2%
of the participants included: solvents, GHB, nutmeg,
benzodiazepines, MDA, opiates and barbiturates. Three
participants who had not smoked cannabis but had used
other drugs (LSD, cocaine and morphine) were included
in the analyses reported below as non-cannabis users.
SPQB means and standard deviations (in brackets) for
the entire sample were as follows: SPQB-CP: 3.03 (2.10),
SPQB-I: 2.65 (2.33), SPQB-D: 1.82 (1.76) and for the
SPQB total score 7.50 (4.71). The distribution of the
SPQB total score approximated to normal but each of the
subscales required (logarithmic) transformation prior to
statistical analysis. There were no signiﬁcant differences
between those who reported having used cannabis and
those who had not on the SPQB total or any of the SPQB
subscales.
Relationship between SPQ-B Scores and CEQ
Subscales
In the sample who reported ever using cannabis (n =
99, 72%) the means for the subscales from the CEQ were
as follows: Pleasurable Experiences 39.94 (9.94), Psychosis-Like Experiences 43.12 (12.98) and After-Effects
22.71 (9.31). In each case, distribution of data was approximately normal. Bivariate correlational analyses
were performed in line with the study hypotheses indicating signiﬁcant positive correlations between the Psychosis-Like Experiences subscale and the SPQB-D subscale
(r = 0.40, p ! 0.01), the SPQB-CP subscale (r = 0.33,
p ! 0.01) and the SPQB total score (r = 0.44, p ! 0.01).
The After-Effects subscale was also correlated with the
SPQB-D subscale (r = 0.35, p ! 0.01), the SPQB-P subscale (r = 0.47, p ! 0.01) and the SPQB total score (r =
0.49, p ! 0.01). The Pleasurable Experiences subscale was
not signiﬁcantly correlated with any SPQB scores.
There were 51 participants who had used only cannabis. When the correlational analysis was restricted to only
these participants the results remained largely similar to
those reported above. There were positive correlations
between the Psychosis-Like Experiences subscale and the
SPQB-CP (r = 0.30, p ! 0.05), the SPQB-D (r = 0.40, p !
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0.01) and the SPQB total (r = 0.38, p ! 0.01). The AfterEffects subscale was also correlated with the SPQB-CP
(r = 0.44, p ! 0.01) and the SPQB total (r = 0.39, p ! 0.01).

Discussion

This paper reports on the concurrent and subsequent
effects of recreational cannabis use in a sample of healthy
respondents using a newly developed scale (the CEQ) to
examine subjective experiences. The modest sample size
in this exploratory study was partly compensated for by
the high rate of reported cannabis use (72%). The CEQ
appears to be an acceptable and useful instrument which
generates quantitative data about subjective experiences.
Unlike previous research [7–11] we did not ﬁnd that
cannabis users had higher schizotypy scores than non-users. In our sample at least, it seems that schizotypal traits
do not predispose young people to smoke cannabis, nor
does cannabis use, per se, elevate schizotypy scores. It
may be that this ‘failure to replicate’ is partly a consequence of the high rates of reported cannabis use in our
sample: Verdoux et al. [15] found considerably lower
rates of recent or current drug use in their French cohort,
for example. However, the main hypotheses were conﬁrmed in that amongst individuals who smoked (or had
ever smoked) cannabis, high schizotypy was associated
with a greater likelihood of experiencing both psychosislike features during drug use and unpleasant after-effects.
Pleasurable experiences, on the other hand, were equally
reported across the sample and apparently unrelated to
schizotypy score.
Despite the comparatively high rate of cannabis use in
our sample, the increased reporting of psychosis-like experiences in cannabis users with high schizotypy scores
broadly supports the ﬁndings of Verdoux et al. [15]. Taken together, both sets of results suggest that those most
prone to psychosis, whilst experiencing similar levels of
the pleasurable experiences of cannabis as other respondents, are more likely to additionally experience psychosis-like experiences and after-effects.
A limitation of the current study is that participants
were not screened for the presence of psychiatric illnesses.
The collection of the data in this study did not permit follow-up which would have presented the opportunity for a
screening tool to be used. Similarly, a family history of
psychiatric illness may impact upon participants’ experiences during cannabis use, assuming that a biological individual difference mediates cannabis response. The data
were collected from students, some of whom were known
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to the researchers; therefore every effort was made to permit complete anonymity for the participants, and this to
some extent restricted the data which could be collected.
Individuals who have high schizotypy scores and who
report psychosis-like responses to cannabis may represent
a particularly high risk group for psychosis. Delta-9-tetrahydrocannabinol is the principle active ingredient in
cannabis [22]. In humans, it binds to cannabinoid (CB1)
receptors localized in the prefrontal cortex, basal ganglia
and hippocampus [23] where it has a dopamine agonist
action [24, 25]. The heightened sensitivity of dopamine
systems observed in acute schizophrenia [26] may also be
present to some degree along the psychosis continuum
[e.g. 27]. This would explain why high scoring schizotypes
who use cannabis are more likely to have psychosis-like
experiences and pronounced after-effects than their low
scoring counterparts. There is an overlap in the characteristics of schizotypal personality, in particular the positive aspects (e.g. unusual perceptual experiences) and

possible responses to recreational drug use. However,
Verdoux et al. [13] have shown that psychosis proneness
does inﬂuence people’s experiences for a time following
cannabis use, lending some support to the notion that individual differences in response to cannabis may be related to psychosis proneness. Perhaps individuals who
have many features of the schizotypal trait prior to cannabis use experience psychosis-like responses to cannabis
use as well as more after-effects, leading to an increase in
both the negative and positive aspects of schizotypy.
However, those who do not have schizotypal characteristics only experience the unusual perceptual experiences
commonly reported during cannabis use and do not have
the ‘amotivational’ after-effects. This would mean only
the positive aspects of schizotypy would increase. Testing
such a hypothesis would require a longitudinal study involving adolescents prior to their exposure to cannabis
and it may shed some further light on the relationship
between cannabis and psychotic symptoms.
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